Literature DB >> 24756763

Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Shannon K Crowley1, Susan S Girdler.   

Abstract

RATIONALE: A robust epidemiological literature suggests an association between chronic stress and the development of affective disorders. However, the precise biological underpinnings of this relationship remain elusive. Central to the human response and adaptation to stress, activation and inhibition of the hypothalamic pituitary adrenal (HPA) axis involves a multi-level, multi-system, neurobiological stress response which is as comprehensive in its complexity as it is precarious. Dysregulation in this complex system has implications for human stress related illness.
OBJECTIVES: The pioneering research of Robert Purdy and colleagues has laid the groundwork for advancing our understanding of HPA axis regulation by stress-derived steroid hormones and their neuroactive metabolites (termed neurosteroids), which are potent allosteric modulators of GABAA receptor function in the central nervous system. This review will describe what is known about neurosteroid modulation of the HPA axis in response to both acute and chronic stress, particularly with respect to the current state of our knowledge of this process in humans.
RESULTS: Implications of this research to the development of human stress-related illness are discussed in the context of two human stress-related psychiatric disorders - major depressive disorder and premenstrual dysphoric disorder.
CONCLUSIONS: Neurosteroid-mediated HPA axis dysregulation is a potential pathophysiologic mechanism which may cross traditional psychiatric diagnostic classifications. Future research directions are identified.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756763      PMCID: PMC4135030          DOI: 10.1007/s00213-014-3572-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  202 in total

1.  Serum allopregnanolone in women with postpartum "blues".

Authors:  R E Nappi; F Petraglia; S Luisi; F Polatti; C Farina; A R Genazzani
Journal:  Obstet Gynecol       Date:  2001-01       Impact factor: 7.661

Review 2.  Social isolation stress-induced aggression in mice: a model to study the pharmacology of neurosteroidogenesis.

Authors:  Kinzo Matsumoto; Graziano Pinna; Giuli Puia; Alessandro Guidotti; Erminio Costa
Journal:  Stress       Date:  2005-06       Impact factor: 3.493

3.  Double-blind treatment of major depression with dehydroepiandrosterone.

Authors:  O M Wolkowitz; V I Reus; A Keebler; N Nelson; M Friedland; L Brizendine; E Roberts
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

Review 4.  The olfactory bulbectomized rat as a model of depression.

Authors:  B E Leonard
Journal:  Pol J Pharmacol Pharm       Date:  1984 Sep-Oct

Review 5.  Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans.

Authors:  O T Wolf; C Kirschbaum
Journal:  Brain Res Brain Res Rev       Date:  1999-11

6.  Effects of acute progesterone administration upon responses to acute psychosocial stress in men.

Authors:  Emma Childs; Nicholas T Van Dam; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.157

7.  Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

Authors:  I Sundström; A Andersson; S Nyberg; D Ashbrook; R H Purdy; T Bäckström
Journal:  Neuroendocrinology       Date:  1998-02       Impact factor: 4.914

8.  Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

Authors:  Peter J Schmidt; Robert C Daly; Miki Bloch; Mark J Smith; Merry A Danaceau; Linda Simpson St Clair; Jean H Murphy; Nazli Haq; David R Rubinow
Journal:  Arch Gen Psychiatry       Date:  2005-02

9.  The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus.

Authors:  Elif Engin; Dallas Treit
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

10.  Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.

Authors:  Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman
Journal:  Arch Gen Psychiatry       Date:  2003-02
View more
  29 in total

1.  Anesthesia with sevoflurane in neonatal rats: Developmental neuroendocrine abnormalities and alleviating effects of the corticosteroid and Cl(-) importer antagonists.

Authors:  Changqing Xu; Sijie Tan; Jiaqiang Zhang; Christoph N Seubert; Nikolaus Gravenstein; Colin Sumners; Terrie Vasilopoulos; Anatoly E Martynyuk
Journal:  Psychoneuroendocrinology       Date:  2015-06-25       Impact factor: 4.905

2.  Neuroactive steroid levels and cocaine use chronicity in men and women with cocaine use disorder receiving progesterone or placebo.

Authors:  Verica Milivojevic; Jonathan Covault; Gustavo A Angarita; Kristen Siedlarz; Rajita Sinha
Journal:  Am J Addict       Date:  2018-12-11

3.  Propofol, but not etomidate, increases corticosterone levels and induces long-term alteration in hippocampal synaptic activity in neonatal rats.

Authors:  Changqing Xu; Christoph N Seubert; Nikolaus Gravenstein; Anatoly E Martynyuk
Journal:  Neurosci Lett       Date:  2016-02-26       Impact factor: 3.046

Review 4.  Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model.

Authors:  Jennifer L Gordon; Susan S Girdler; Samantha E Meltzer-Brody; Catherine S Stika; Rebecca C Thurston; Crystal T Clark; Beth A Prairie; Eydie Moses-Kolko; Hadine Joffe; Katherine L Wisner
Journal:  Am J Psychiatry       Date:  2015-01-13       Impact factor: 18.112

5.  Heightened stress response and cognitive impairment after repeated neonatal sevoflurane exposures might be linked to excessive GABAAR-mediated depolarization.

Authors:  Guanghai Liu; Tiangui Zhu; Aihua Zhang; Feng Li; Weidong Qian; Bin Qian
Journal:  J Anesth       Date:  2016-07-19       Impact factor: 2.078

6.  Prevention of unpredictable chronic stress-related phenomena in zebrafish exposed to bromazepam, fluoxetine and nortriptyline.

Authors:  Matheus Marcon; Ana P Herrmann; Ricieri Mocelin; Cassiano L Rambo; Gessi Koakoski; Murilo S Abreu; Greicy M M Conterato; Luiza W Kist; Maurício R Bogo; Leila Zanatta; Leonardo J G Barcellos; Angelo L Piato
Journal:  Psychopharmacology (Berl)       Date:  2016-08-25       Impact factor: 4.530

Review 7.  Premenstrual Dysphoric Disorder: Epidemiology and Treatment.

Authors:  Liisa Hantsoo; C Neill Epperson
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

8.  Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder.

Authors:  Tory A Eisenlohr-Moul; David R Rubinow; Crystal E Schiller; Jacqueline L Johnson; Jane Leserman; Susan S Girdler
Journal:  Psychoneuroendocrinology       Date:  2016-02-01       Impact factor: 4.905

9.  Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study.

Authors:  Shannon K Crowley; Todd K O'Buckley; Crystal E Schiller; Alison Stuebe; A Leslie Morrow; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2016-02-09       Impact factor: 4.530

10.  Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.

Authors:  Kristina M Deligiannidis; Aimee R Kroll-Desrosiers; Shunyan Mo; Hien P Nguyen; Abby Svenson; Nina Jaitly; Janet E Hall; Bruce A Barton; Anthony J Rothschild; Scott A Shaffer
Journal:  Psychoneuroendocrinology       Date:  2016-05-09       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.